Effects of GLP-1 on Chronic Heart Failure

Shi Yang68 enrolled

Overview

The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide could improve left ventricular function in patients with acute myocardial infarction. However, the effects of GLP-1 on chronic heart failure patients with type 2 diabetes remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Heart Failure

Interventions

GLP-1DRUG

Liraglutide were taken daily for 3 months

PlaceboDRUG

Placebo were taken daily for 3 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic heart failure patients with type 2 diabetes (NYHA-class I, II or III) were eligible for the study Exclusion Criteria: * CHF (NYHA class IV) * Type 1 diabetes * Hospitalisation due to incompensated heart disease within 30 days prior to randomisation * Myocardial infarction within the past 3 months before screening * Coronary revascularisation within the past 3 months before screening * Atrial fibrillation with ventricular frequency \>100/min in rest * ECG suggestive of malignant ventricular arrhythmia * Prolonged QT-interval (\>500 ms) * Valvular heart disease * Current myocardial or pericardial infection * Obstructive hypertrophic cardiomyopathy * Cancer unless in complete remission for ≥5 years * Acute pancreatitis * Compromised kidney function (eGFR \<30 mL/min), dialysis or kidney transplantation * History of thyroidea adenoma or carcinoma

Locations (1)

PLA General Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

left ventricular ejection fraction measured by 3D echocardiography

The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by 3D echocardiography at 3 months.

Time frame: 3 months

Secondary Outcomes

plasma NT-proBNP levels

a change in plasma NT-proBNP levels at 3 months after treatment

Time frame: 3 months

a change in 6-minute walk distance

The change in 6-minute walk distance at 3 months after treatment.

Time frame: 3 months

differences in the incidences of treatment-emergent adverse events

differences in the incidences of treatment-emergent adverse events at 3 months

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.